Create your account

Analyse episodes, create alerts, spot trends before they go mainstream

Already have an account? Sign in

Companies

Biogen

Mentioned in 5 analyzed podcast episodes across 4 shows

Mentioned On

CNBC's "Fast Money"Biotech HangoutPharma and BioTech DailyRelentless

Episode Mentions

CNBC's "Fast Money"

CNBC's "Fast Money" · May 14, 2026

Cerebras Surges In Nasdaq Debut… And Wheelin’ & Dealin’ In China 5/14/26

“Experimental Alzheimer's drug failed dose-response trial but advancing to phase three; stock volatile, trading at 11x forward earnings with diversified pipeline”

Cerebras IPO valuation and customer concentration riskAI infrastructure bottlenecks: memory vs. compute vs. powerTaiwan semiconductor geopolitical leverage in US-China trade
View Analysis
Biotech Hangout

Biotech Hangout · May 8, 2026

Episode 182 - May 8, 2026

“Co-developer of tofersen (SOD1 ALS drug); FDA approved based on neurofilament reduction without placebo control”

Biotech Secondary Capital Raises and Market SaturationFDA Regulatory Uncertainty and Commissioner McCary LeadershipM&A Activity in Biotech and Venture Capital Returns
View Analysis
Pharma and BioTech Daily

Pharma and BioTech Daily · Apr 30, 2026

AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily

“Competing in Alzheimer's disease market with Lakembi therapy against Eli Lilly's Kisunla”

FDA Real-Time Clinical Trial Review PilotAstraZeneca UK Investment and Drug PricingOncology Market Consolidation Strategy
View Analysis
CNBC's "Fast Money"

CNBC's "Fast Money" · Mar 31, 2026

Stocks Rally On Optimism For End Of Iran War… And Apple’s Mag-7 Outperformance 3/31/26

“Acquiring Apellis Pharmaceuticals for $5.6 billion to offset shrinking multiple sclerosis revenue and failed Alzheimer's bet”

Iran War Ceasefire Negotiations and Geopolitical RiskOil Price Dynamics and Energy IndependenceNike Earnings Miss and Athletic Wear Sector Weakness
View Analysis
Relentless

Relentless · Feb 14, 2026

The Quest to Cure Alzheimer's | Sacha Schermerhorn, Babylon Bio

“Developed Aducanumab, the controversial Alzheimer's drug that cleared amyloid but showed no cognitive benefit”

Alzheimer's Disease Drug DevelopmentTau Pathology and Neurofibrillary TanglesAmyloid Cascade Hypothesis
View Analysis